Emerging Infectious Diseases (Jun 2011)

Cefepime-Resistant Pseudomonas aeruginosa

  • Ehimare Akhabue,
  • Marie Synnestvedt,
  • Mark G. Weiner,
  • Warren B. Bilker,
  • Ebbing Lautenbach

DOI
https://doi.org/10.3201/eid1706.100358
Journal volume & issue
Vol. 17, no. 6
pp. 1037 – 1043

Abstract

Read online

Resistance to extended-spectrum cephalosporins complicates treatment of Pseudomonas aeruginosa infections. To elucidate risk factors for cefepime-resistant P. aeruginosa and determine its association with patient death, we conducted a case–control study in Philadelphia, Pennsylvania. Among 2,529 patients hospitalized during 2001–2006, a total of 213 (8.4%) had cefepime-resistant P. aeruginosa infection. Independent risk factors were prior use of an extended-spectrum cephalosphorin (p<0.001), prior use of an extended-spectrum penicillin (p = 0.005), prior use of a quinolone (p<0.001), and transfer from an outside facility (p = 0.01). Among those hospitalized at least 30 days, mortality rates were higher for those with cefepime-resistant than with cefepime-susceptible P. aeruginosa infection (20.2% vs. 13.2%, p = 0.007). Cefepime-resistant P. aeruginosa was an independent risk factor for death only for patients for whom it could be isolated from blood (p = 0.001). Strategies to counter its emergence should focus on optimizing use of antipseudomonal drugs. 1Current affiliation: Duke University School of Medicine, Durham, North Carolina, USA.

Keywords